Blueberry Study Aimed at Improving Cognition and Peripheral Blood Flow

Blood Pressure Clinical Trial

Official title:

Metabolic Mechanisms Underlying the Responsiveness to Blueberry Interventions Aimed at Improving Cognition and Peripheral Blood Flow

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04015258
• Other study ID #: Research Ethics 10113
• Status: Completed
• Phase: N/A
• Start date: January 1, 2019
• Est. completion date: January 1, 2020

Study information

• Verified date: July 2019
• Source: Northumbria University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Blueberries are rich in the content of a variety of biologically active chemicals that contribute to their health properties. The consumption of blueberries has beneficial effects on vascular function and brain health and function. Blueberries are present in human diet in a number of forms, but the investigator do not know which form is best for health and why people respond differently to eating blueberries.

The aim of the present study is to assess the effects of 1 week's supplementation of whole blueberries or freeze-dried blueberry powder or encapsulated blueberry components on vascular function and brain health and function. Investigators will then categorise participants as those who have large effects of the intervention (responders) and those that don't show much effect at all (non-responders). Then the investigators will look into the role that genes play in this response and determine if metabolism is similar in these groups of participants. Any changes in participants' brain health and vascular function will be linked to these metabolic and genomic pathways, and this will help the investigators to further understand how blueberry consumption can benefit human health.

Description:

Study design: The present study will supply either 160 g of fresh whole blueberry (4 handful portion) or 20 g of freeze-dried blueberry powder (measured with tablespoon provided; equivalent to 160 g of whole fresh blueberry), or placebo capsule with only microcrystalline cellulose (approx. 10 g, they will be blinded that this is encapsulated blueberry extract components) to 80 subjects on separate occasions with age range of 18-60 years old for 1 week with 1 week of washout period. Fresh blueberries will be purchased from local supermarkets; freeze-dried blueberry powder will be purchased from Lio-Licious freeze-dried fruits range; the microcrystalline cellulose will be purchased from Blackburn Distributions. There is no outside interest that could constitute commercial conflict of interest.

Methodology and sampling strategy: a randomised crossover design will be implemented. The study is a quantitative experiment and participants will be recruited through opportunity sampling.

Data collection: On each visit, cognition data will be obtained from computerised testing system COMPASS. Blood pressure will be obtained using fully automatic oscillometric device. On visits 2-7, PWV value is obtained by SphygmoCor; untargeted metabolomics and genomic data will be obtained from blood and urine sample collection.

For data analysis: The identification of responders to the treatments will be done by the calculation of response level first: response level = (change from baseline score/baseline score) x 100%. The calculated percentage will be used to characterise subjects from lowest response to highest response level. The association among -omics biomarkers and cognitive tests/endothelial parameters, lipid status under each treatment will be analysed using linear regression models after adjusting for confounding factors like age. Pathway analysis will be used to identify metabolic pathways that characterise responders and non-responders. Pathways will be identified using discriminatory metabolites from metabolomics and SNP analysis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: January 1, 2020
• Est. primary completion date: January 1, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Interested in taking part in the study

• Healthy

• Aged 18-60 years (inclusive)

Exclusion Criteria:

• Smoking

• Aged under 18 or over 60

• Blood Pressure = 145/100 mmHg and are taking medication

• Have vascular disease, or other cardiac abnormalities

• Have previously suffered any head injuries, history of seizures or other neurological disorders

• Have any metabolic disorders, malabsorption syndromes or gastrointestinal complications

• Current use of above disease relevant prescription medications (excluding contraception)

• Irregular bowel function (less than 1 bowel movement per day)

• Regularly consume blueberries/blueberry-contained products more than twice per week

• Have regularly used nutritional supplements or medications within the previous 3 months (defined as more than 3 consecutive days or 4 days in total)

• Learning difficulties and dyslexia

• Visual impairment that cannot be corrected with glasses or contact lenses including colour blindness

• Currently suffer from migraines (> 1 per month)

• Body mass index (BMI) under 18.5 or over 30

• Pregnancy, seeking to become pregnant, or current lactation

• Inability to complete all of the study assessments

• Current participation in other clinical or nutrition intervention studies

• Not proficient in English equivalent to IELTS band 6 or above

• Have any known active infections

Related Conditions & MeSH terms

• Blood Pressure
• Cognitive Change
• Vascular Stiffness

Intervention

Dietary Supplement:
• Blueberries
fresh spanish blueberries
• Blueberry powder
freeze-dried blueberry powder
• Blueberry components capsules
encapsulated blueberry components (microcrystalline cellulose powder in actual)

Locations

Country	Name	City	State
United Kingdom	Northumbria University	Newcastle upon Tyne	Tyne And Wear

Sponsors (1)

Lead Sponsor	Collaborator
Northumbria University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Accuracy of participant recalling word list Immediately	will be assessed via COMPASS (Computerised Mental Performance Assessment System) tasks by participants recalling word list immediately after displays; the result will be presented as accuracy (%) and as an assessment of short-term memory	1 minute
Primary	Correct responses of participants counting down from certain number by subtracting 3	will be assessed via COMPASS tasks by participants counting down from certain number by threes. The result will be presented as correct responses and as an assessment of executive function	5 minutes
Primary	Correct responses of participants counting down from certain number by subtracting 7	will be assessed via COMPASS tasks by participants counting down from certain number by sevens, the result will be presented as correct responses and as an assessment of executive function	5 minutes
Primary	Reaction time of participants' vigilance during rapid visual tracking and accurate selection of target digit stimuli	will be assessed via COMPASS tasks by measuring participants' vigilance during rapid visual tracking and accurate selection of target stimuli, presented by reaction time in millisecond (ms), as an assessment of attention and psychomotor speed	5 minutes
Primary	Accuracy of participant recalling word list 30 minutes after displays	will be assessed via COMPASS tasks by participants recalling word list after 30 minutes, the result will be presented as accuracy (%) and as an assessment of memory	5 minutes
Primary	Brachial-radial distance	brachial-radial distance in meters (m), will be measured by tape	1 minute
Primary	Pulse wave time	time of the pulse wave moves down from brachial to radial artery in seconds (s), will be measured by Sphygmocor (ScanMed medical)	10 minutes
Primary	Pulse wave velocity (PWV)	will be measured by Sphygmocor (ScanMed medical), by outcome 7 pulse wave time (s) dividing outcome 6 brachial-radial distance (m), PWV will be presented in the units of m/s, as an assessment of endothelial function	10 minutes
Primary	Blood Pressure	will be assessed by BP monitor and reported in the units of mm Hg	10 minutes
Secondary	Inter-cellular Adhesion Molecules (ICAMs) and Vascular Cell Adhesion Molecules (VCAMs)	Endothelial dysfunction's biomarkers (ICAMs and VCAMs) assessed by ELISA Kits and reported in the units of U/mL	1 day
Secondary	C-reactive Protein (CRP)	Endothelial dysfunction's biomarkers (CRP) assessed by ELISA Kits in the units of mg/L	1 day
Secondary	Plasma Lipid Status	Total and High-density lipoprotein (HDL-), Low-density lipoprotein (LDL-) cholesterol and triglycerides assessed by outsourcing to the local hospital, the results will be reported in the units of mmol/L	1 day
Secondary	Untargeted Plasma and Urine Metabolites	liquid-chromatography mass spectrometry-based techniques (LCMS) will be applied to identify untargeted metabolites in the plasma and urine samples	1 day
Secondary	Single Nucleotide Polymorphisms (SNPs)	SNP arrays will be applied for genotyping participants' DNA collected from the buffy coat of the blood sample, following the removal of plasma	7 days